Hypogonadotropic Hypogonadism (HH), or secondary hypogonadism, is an endocrine disorder caused by deficient gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus or reduced gonadotropin (FSH, LH) secretion from the anterior pituitary gland. This leads to low serum testosterone and impaired spermatogenesis, resulting in severe oligospermia or azoospermia.
How to Read Your Hormone Panel & Semen Metrics
| Hormone / Metric | Normal Reference Range | Hypogonadotropic Result | Diagnostic Significance |
|---|---|---|---|
| Total Testosterone | 300 – 1000 ng/dL | < 150 ng/dL | Reflects absent Leydig cell stimulation and severe testosterone deficiency. |
| Serum FSH | 1.5 – 12.4 mIU/mL | < 1.0 mIU/mL (or Low) | Confirms central (pituitary/hypothalamic) failure rather than primary testicular damage. |
| Serum LH | 1.7 – 8.6 mIU/mL | < 1.0 mIU/mL (or Low) | Inadequate pituitary signaling for testicular steroidogenesis. |
| Semen Output | > 15 million / mL | Severe Oligo / Azoospermia | Complete arrest of the spermatogenic cycle due to lack of FSH stimulation. |
Diagnostic Workup Logic
- Morning Fasting Endocrine Panel: Serial measurements of Total Testosterone, Free Testosterone, FSH, LH, and Prolactin.
- Pituitary MRI: Mandatory to evaluate pituitary adenomas, hypothalamic lesions, or micro-adenomas when HH is confirmed.
- Olfactory Testing: Differentiates Kallmann syndrome (characterized by anosmia/hyposmia) from normosmic idiopathic hypogonadotropic hypogonadism.
Etiology & Classifications
- Congenital Forms: Kallmann syndrome (congenital absence of GnRH neurons associated with loss of smell) and normosmic idiopathic HH.
- Acquired Forms: Pituitary macroadenomas (prolactinomas), craniopharyngiomas, severe systemic illnesses, head trauma, and hemochromatosis.
- Steroid-Induced (ASIH): Suppression of the HPG axis secondary to exogenous testosterone or anabolic-androgenic steroid abuse.
Clinical Management & Hormonal Therapy
- Combined Gonadotropin Induction Therapy: Standard therapy involves human chorionic gonadotropin (hCG, 1000–2000 IU subcutaneously 2–3 times weekly) to stimulate Leydig cells, followed by recombinant or highly purified FSH (75–150 IU 3 times weekly) to drive spermatogenesis.
- Pulsatile GnRH Therapy: Delivered via a programmable subcutaneous infusion pump in cases of hypothalamic GnRH deficiency.
- Strict Contraindication: Exogenous testosterone monotherapy must never be used for men seeking fertility, as it further suppresses gonadotropin release and stops sperm production entirely.
